Edition:
United Kingdom

CytomX Therapeutics Inc (CTMX.OQ)

CTMX.OQ on NASDAQ Stock Exchange Global Select Market

20.56USD
8 Dec 2017
Change (% chg)

$0.44 (+2.19%)
Prev Close
$20.12
Open
$20.33
Day's High
$20.67
Day's Low
$19.99
Volume
107,575
Avg. Vol
137,359
52-wk High
$24.50
52-wk Low
$10.44

Chart for

About

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development... (more)

Overall

Beta: --
Market Cap(Mil.): $792.65
Shares Outstanding(Mil.): 36.87
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Cytomx Therapeutics Says FDA Accepts IND For CTLA-4 Probody Therapeutic

* CYTOMX THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR CTLA-4 PROBODY THERAPEUTIC

28 Nov 2017

BRIEF-CytomX reports Q3 loss per share $‍0.28​

* CytomX announces third quarter 2017 financial results and operational progress

07 Nov 2017

BRIEF-CytomX Therapeutics appoints Charles Fuchs to board of directors

* CytomX Therapeutics Inc appoints Charles S. Fuchs, M.D., MPH to board of directors Source text for Eikon: Further company coverage:

24 Oct 2017

BRIEF-Cytomx Therapeutics Q2 loss per share $ 0.69​

* Cytomx announces second quarter 2017 financial results and mid-year update webcast conference call

07 Aug 2017

BRIEF-Canaan IX LP dissolves passive stake in Cytomx Therapeutics as of June 7 - SEC filing

* Canaan IX LP dissolves passive stake in Cytomx Therapeutics Inc as of June 7 - SEC filing

07 Jul 2017

BRIEF-BVF Partners LP reports 5.5 pct passive stake in CytomX Therapeutics as of June 19 - SEC Filing

* BVF Partners LP reports 5.5 percent passive stake in CytomX Therapeutics Inc as of June 19 - SEC Filing Source text: [http://bit.ly/2trugL5] Further company coverage:

30 Jun 2017

BRIEF-CytomX achieves development milestone in collaboration with AbbVie

* CytomX achieves development milestone in strategic oncology collaboration with AbbVie for CD71-targeting probody drug conjugate

29 Jun 2017

Earnings vs. Estimates